Reportlinker Adds Triple Analysis: Melanoma, Pancreatic Cancer and Angiogenesis
NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Triple Analysis: Melanoma, Pancreatic Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Melanoma
The melanoma report part comprises defined and up to date development strategies for 124 melanoma drugs within the portfolio of 95 investigators, from Preclinical to Marketed. This report part extensively analyses 118 identified targets of melanoma drugs, organized into 94 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Currently Druggable in Melanoma: A Drug Target Competitive Analysis
Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 213 pancreatic cancer drugs within the portfolio of 137 investigators, from Ceased to Marketed. This report part extensively analyses 171 identified targets of pancreatic cancer drugs, organized into 142 drug target profiles, and assesses them in pancreatic cancer.
This part is based on the following publication:
Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?
Part III: Angiogenesis
The angiogenesis report part comprises defined and up to date development strategies for 239 drugs affecting angiogenesis in oncology within the portfolio of 148 investigators, from Preclinical to Marketed. This report part extensively analyses 174 identified targets of angiogenesis affecting drugs, organized into 167 drug target strategies, and assesses them in 64 different cancer indications.
This part is based on the following publication:
Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:
* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
* Supporting development of integrative molecule, pathway and disease area strategies
* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.
Key Topics Covered:
Part I: Melanoma
5 How to Use this Report 14
12 Drug Target Profiles of Melanoma Drugs (118 Drug Targets) 70-213
14 The Progression and Maturity of Melanoma Targets (94 Drug Target Strategies and 124 Drugs) 218-233
15 Targets by R&D Approach in Melanoma (7 Different Compound Strategies) 234-251
16 Melanoma Targets by Companies (95 Investigators) 252-261
18 Drug Index 263
19 Company Index 266
Figures: Includes 6 Figures
Tables: Includes 46 Tables
Total Number of Pages: 268
Part II: Pancreatic Cancer
5.1 The Scope of this Report 24
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (171 Drug Targets) 28
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Strategies Identified in the Pancreatic Cancer Therapeutic Pipeline? (142 Drug Target Strategies and 213 Drugs) 333
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 374
9 Pipeline and Portfolio Planning: Competitive Benchmarking of Pancreatic Cancer Therapeutic Pipeline by Investigator (137 Investigators) 408-599
11 Drug Index 601
12 Company Index 606
Figures: Includes 5 Figures
Tables: Includes 193 Tables
Total Number of Pages: 610
Part III: Angiogenesis
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (174 Drug Targets) 39-366
7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167 Drug Target Strategies and 239 Drugs) 367-437
8 Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies) 438-485
9 Selecting Cancer Indications for Angiogenesis Affecting Drugs in Oncology (64 Cancer Indications) 486-643
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148 Investigators) 644-1211
10 Disclaimer 1212
11 Drug Index 1213
12 Company Index 1221
Figures: Includes 7 Figures
Tables: Includes 300 Tables
Total Number of Pages: 1227
To order this report:
Drug Discovery and Development Industry: Triple Analysis: Melanoma, Pancreatic Cancer and Angiogenesis
Drug Discovery and Development Business News
Check our Company Profile, SWOT and Revenue Analysis!
Contact |
|
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article